Clare Laxton, Associate Director for Policy and Influencing at CLIC Sargent, said:
“We hugely welcome the introduction of CAR-T therapy for children and young people with cancer, which will provide more personalised treatment and could save lives.
“But we know that families are already facing huge travel costs just to get their child to treatment. More specialised treatment in fewer places means increased travel and accommodation costs for parents to access these revolutionary new treatments, at a time when they are already burdened by mounting debts.
“Getting your child the lifesaving treatment they need shouldn’t come with a price tag for parents. Our research shows that young cancer patients are travelling twice as far and spending twice as much on getting to and from the hospital than adults with cancer. This is yet more evidence why a Young Cancer Patient Travel Fund is so vitally needed.”